Overview

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Addpharma Inc.
Treatments:
Amlodipine
Telmisartan